Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$50.21

0.25 (0.50%)

14:09
09/29/19
09/29
14:09
09/29/19
14:09

Bristol-Myers announces five-year results from Phase 3 CheckMate -067 trial

Bristol-Myers Squibb announced five-year results from the Phase 3 CheckMate -067 clinical trial, which continues to demonstrate improved overall survival with the first-line combination of Opdivo plus Yervoy, versus Yervoy alone, in patients with advanced metastatic melanoma. With a minimum follow-up of 60 months, five-year overall survival rates were 52% for the Opdivo plus Yervoy combination, 44% for Opdivo alone, and 26% for Yervoy alone. The safety profile for Opdivo plus Yervoy was consistent with prior findings, with no new safety signals and no additional treatment-related deaths. At this five-year analysis, treatment-related adverse events were consistent with those previously reported and occurred in 300 patients in the combination group, 271 patients in the Opdivo group, and 268 patients in the Yervoy group; grade 3/4 adverse events occurred in 186, 73, and 86 patients, respectively. The percentage of patients experiencing an objective response remained stable at 58% for Opdivo plus Yervoy, 45% for Opdivo alone, and 19% for Yervoy, while the percentage of patients experiencing a complete response continued to increase, with complete response rates at five years of 22% for Opdivo plus Yervoy, 19% for Opdivo alone, and 6% for Yervoy alone. In addition, the proportion of patients alive and treatment-free was 74% in the Opdivo plus Yervoy group and 58% and 45% for Opdivo alone and Yervoy alone, respectively. Among patients with BRAF-mutant or wild-type tumors, the rate of overall survival at five years was 60% and 48%, respectively, in patients who received Opdivo plus Yervoy; 46% and 43% for Opdivo alone; and 30% and 25% for Yervoy alone. Health-related quality of life continued to be maintained during or following treatment with Opdivo alone or the combination of Opdivo plus Yervoy.

  • 31

    Oct

BMY Bristol-Myers
$50.21

0.25 (0.50%)

08/14/19
ATLE
08/14/19
UPGRADE
Target $63
ATLE
Overweight
Bristol-Myers upgraded to Overweight from Neutral at Atlantic Equities
Atlantic Equities analyst Steve Chesney upgraded Bristol-Myers Squibb to Overweight from Neutral and raised his price target for the shares to $63 from $51.
08/14/19
08/14/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Evercore Partners (EVR) upgraded to Neutral from Sell at Goldman Sachs with analyst Richard Ramsden saying believes that stronger U.S. large cap deal activity than he previously expected should support Evercore's revenues. 2. Sanofi (SNY) upgraded to Buy from Neutral at UBS with analyst Laura Sutcliffe saying she sees signs of a turnaround for the company and believes its pipeline can fixed ahead of patent expiration. 3. Bristol-Myers (BMY) upgraded to Overweight from Neutral at Atlantic Equities. 4. Horizon Pharma (HZNP) upgraded to Outperform from Market Perform at BMO Capital with analyst Gary Nachman citing the company's "strong" Q2 results driven by Krystexxa. 5. Ferrari (RACE) upgraded to Buy from Neutral at Goldman Sachs with analyst George Galliers citing the company's Q2 results earlier this month. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/19/19
MZHO
08/19/19
DOWNGRADE
MZHO
Neutral
Amgen, Celgene downgraded to Neutral on valuation at Mizuho
As previously reported, Mizuho analyst Salim Syed downgraded Amgen (AMGN) and Celgene (CELG), each to Neutral from Buy, "solely" on the stock's current trading prices nearing what the analyst views as appropriate valuations. Amgen has run up over the last week by about 10% following a "very clean Enbrel litigation win," but the stock price now gives full credit for its Enbrel IP, said Syed, who raised his price target on Amgen shares to $212 from $208. He also cut his price target on Celgene shares to $100 from $103, based on a calculation of one Bristol-Myers (BMY) share being worth $47, plus $50 cash per share and $3 for a risk-adjusted CVR valuation.
08/27/19
RBCM
08/27/19
NO CHANGE
Target $206
RBCM
Sector Perform
Amgen price target raised to $206 from $192 at RBC Capital
RBC Capital analyst Kennen MacKay raised his price target on Amgen to $206, saying that despite the "sticker shock" of its $13.4B deal for the Otezla franchise, the transaction is expected to be immediately accretive to earnings and fitting well with its existing inflammation and immunology portfolio. The analyst believes that Amgen should be able to grow revenue "majorly" over the next 3 years as it leverages Otezla potential with its legal victory on Enbrel, stating that there is a case for its multiple to re-rate higher. MacKay keeps his Sector Perform rating on Amgen shares as he awaits for its emerging pipeline to also "fill the shoes" of its maturing assets.

TODAY'S FREE FLY STORIES

ATVI

Activision Blizzard

$54.69

-0.91 (-1.64%)

15:44
10/18/19
10/18
15:44
10/18/19
15:44
Hot Stocks
U.S. lawmakers urge Activision Blizzard to reverse 'Hearthstone' player's ban »

U.S. Senators Ron Wyden…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 07

    Nov

MFGP

Micro Focus

$15.73

1.16 (7.96%)

15:42
10/18/19
10/18
15:42
10/18/19
15:42
Hot Stocks
Breaking Hot Stocks news story on Micro Focus »

Micro Focus International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TPRE

Third Point Reinsurance

$9.65

0.02 (0.21%)

15:40
10/18/19
10/18
15:40
10/18/19
15:40
Periodicals
Third Point Re reviewing options with help of JPMorgan, Insurance Insider says »

Third Point Reinsurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USO

United States Oil Fund

$11.24

-0.045 (-0.40%)

, SPY

SPDR S&P 500 ETF Trust

$298.84

-0.4 (-0.13%)

15:36
10/18/19
10/18
15:36
10/18/19
15:36
General news
Trump to nominate Deputy Secretary Dan Brouillette for Energy Secretary »

President Donald Trump…

USO

United States Oil Fund

$11.24

-0.045 (-0.40%)

SPY

SPDR S&P 500 ETF Trust

$298.84

-0.4 (-0.13%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APRE

Aprea Therapeutics

$21.89

1.36 (6.62%)

15:35
10/18/19
10/18
15:35
10/18/19
15:35
Hot Stocks
Versant Ventures reports 12.1% passive stake in Aprea Therapeutics »

Versant Ventures…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:29
10/18/19
10/18
15:29
10/18/19
15:29
Conference/Events
Stephens E&P analyst to hold a group luncheon »

Exploration &…

HOG

Harley-Davidson

$36.86

0.16 (0.44%)

15:25
10/18/19
10/18
15:25
10/18/19
15:25
Options
Harley Davidson call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

15:25
10/18/19
10/18
15:25
10/18/19
15:25
General news
Treasury Market Summary »

Treasury Market Summary:…

AJRD

Aerojet Rocketdyne

$45.59

-2.47 (-5.14%)

15:24
10/18/19
10/18
15:24
10/18/19
15:24
Hot Stocks
Aerojet Rocketdyne announces collaboration with Firefly Aerospace »

Aerojet Rocketdyne and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$347.12

-22.01 (-5.96%)

15:21
10/18/19
10/18
15:21
10/18/19
15:21
Periodicals
Boeing said to have provided pilot messages to DOJ in February, Bloomberg says »

A person familiar with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

KSU

Kansas City Southern

$143.99

8.66 (6.40%)

15:19
10/18/19
10/18
15:19
10/18/19
15:19
Recommendations
Kansas City Southern analyst commentary  »

Kansas City Southern…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 13

    Nov

PUMP

ProPetro Holding

$7.99

-0.615 (-7.15%)

15:17
10/18/19
10/18
15:17
10/18/19
15:17
Periodicals
ProPetro Holding being investigated by SEC, Reuters reports »

The Securities and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
10/18/19
10/18
15:17
10/18/19
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
10/18/19
10/18
15:16
10/18/19
15:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLI

Industrial Select Sector SPDR

$76.97

-0.62 (-0.80%)

, XLY

Consumer Discretionary Sector SPDR

$122.39

-0.03 (-0.02%)

15:07
10/18/19
10/18
15:07
10/18/19
15:07
Technical Analysis
On The Fly: Weekly technical notes for S&P 500 »

The S&P 500 (SPX),…

XLI

Industrial Select Sector SPDR

$76.97

-0.62 (-0.80%)

XLY

Consumer Discretionary Sector SPDR

$122.39

-0.03 (-0.02%)

XLV

Health Care Select Sector SPDR

$91.86

-0.23 (-0.25%)

XLF

Financial Select Sector

$28.17

0.12 (0.43%)

XLK

Technology Select Sector SPDR

$81.05

-0.62 (-0.76%)

XLB

S&P Select Materials SPDR

$57.64

0.05 (0.09%)

XLU

Utilities SPDR

$63.86

0.26 (0.41%)

SPY

SPDR S&P 500 ETF Trust

$298.53

-0.71 (-0.24%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

IWM

iShares Trust Russell 2000 Index Fund

$152.79

-0.55 (-0.36%)

, RUT

Russell 2000 Index

$0.00

(0.00%)

15:06
10/18/19
10/18
15:06
10/18/19
15:06
Technical Analysis
On The Fly: Weekly technical notes for Russell 2000 »

For the week the Russell…

IWM

iShares Trust Russell 2000 Index Fund

$152.79

-0.55 (-0.36%)

RUT

Russell 2000 Index

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLGT

Teligent

$0.68

-0.0216 (-3.10%)

15:05
10/18/19
10/18
15:05
10/18/19
15:05
Hot Stocks
Teligent announces FDA approval of Gentamicin Sulfate Cream USP »

Teligent announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIA

Viacom

$24.95

-0.65 (-2.54%)

, VIAB

Viacom

$22.16

-0.45 (-1.99%)

15:05
10/18/19
10/18
15:05
10/18/19
15:05
Periodicals
Comcast, AT&T among bidders for 'South Park' streaming rights, Bloomberg says »

The creators of…

VIA

Viacom

$24.95

-0.65 (-2.54%)

VIAB

Viacom

$22.16

-0.45 (-1.99%)

CMCSA

Comcast

$45.65

-0.29 (-0.63%)

CMCSK

Comcast

$0.00

(0.00%)

DIS

Disney

$131.26

-1.11 (-0.84%)

T

AT&T

$38.45

0.63 (1.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 07

    Nov

  • 14

    Nov

  • 14

    Nov

  • 18

    Nov

  • 19

    Nov

AXP

American Express

$117.55

-1.62 (-1.36%)

15:00
10/18/19
10/18
15:00
10/18/19
15:00
Recommendations
American Express analyst commentary  »

William Blair reiterates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 27

    Oct

  • 13

    Nov

  • 06

    Dec

MFGP

Micro Focus

$14.05

-0.52 (-3.57%)

15:00
10/18/19
10/18
15:00
10/18/19
15:00
Hot Stocks
Breaking Hot Stocks news story on Micro Focus »

Micro Focus International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MFGP

Micro Focus

$14.05

-0.52 (-3.57%)

, OTEX

OpenText

$40.35

-0.495 (-1.21%)

14:58
10/18/19
10/18
14:58
10/18/19
14:58
Hot Stocks
Micro Focus jumps after Bloomberg says rival OpenText considering takeover bid »

Shares of Micro Focus…

MFGP

Micro Focus

$14.05

-0.52 (-3.57%)

OTEX

OpenText

$40.35

-0.495 (-1.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

  • 06

    Nov

  • 19

    Nov

MFGP

Micro Focus

$14.06

-0.51 (-3.50%)

, OTEX

OpenText

$40.37

-0.475 (-1.16%)

14:54
10/18/19
10/18
14:54
10/18/19
14:54
Periodicals
Breaking Periodicals news story on Micro Focus, OpenText »

OpenText weighing…

MFGP

Micro Focus

$14.06

-0.51 (-3.50%)

OTEX

OpenText

$40.37

-0.475 (-1.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

  • 06

    Nov

  • 19

    Nov

MFGP

Micro Focus

$14.06

-0.51 (-3.50%)

14:53
10/18/19
10/18
14:53
10/18/19
14:53
Hot Stocks
Breaking Hot Stocks news story on Micro Focus »

Micro Focus International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOG

Harley-Davidson

$36.89

0.19 (0.52%)

14:49
10/18/19
10/18
14:49
10/18/19
14:49
Periodicals
Harley-Davidson resumes LiveWire production, deliveries, TechCrunch says »

Harley-Davidson (HOG)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

FOMX

Foamix

$3.15

-0.09 (-2.78%)

14:46
10/18/19
10/18
14:46
10/18/19
14:46
Hot Stocks
Breaking Hot Stocks news story on Foamix »

Foamix trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 20

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.